A review on SLE and malignancy

Choi, May Y.; Flood, Kelsey S.; Bernatsky, Sasha; Ramsey‐Goldman, Rosalind; Clarke, Ann E.

doi:10.1016/j.berh.2017.09.013

Cited by 65 publications

(79 citation statements)

References 144 publications

(224 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SLE, RA, and psoriasis are accompanied by chronic joint inflammation, 59,61,62 whereas circulating autoantibodies against intracellular antigens, such as antinuclear antibodies (ANAs) are found in both SLE and SSc. 59,62,63 Increasing evidence from recent studies indicates that lncRNAs help regulate the immune system and might specifically play a critical role in human autoimmune diseases. 13,14,64,65 lncRNAs and SLE.…”

Section: Lncrnas and Human Autoimmune Diseasesmentioning

confidence: 99%

“…SLE, which has a high incidence rate in young women, is a complex systemic AID that involves both the innate and acquired immune systems. 63,66 SLE loses its immune tolerance to nuclear autoantigens and produces ANAs. The production of autoantibodies (AAb) targeting double-stranded DNA (dsDNA) and other nuclear autoantigens are the main characteristic of this disease.…”

Section: Lncrnas and Human Autoimmune Diseasesmentioning

confidence: 99%

“…Although there are considerable clinical differences among human autoimmune diseases (such as SLE, rheumatoid arthritis [RA], MS, and psoriasis), their pathogeneses do exhibit some similarities. SLE, RA, and psoriasis are accompanied by chronic joint inflammation, whereas circulating autoantibodies against intracellular antigens, such as antinuclear antibodies (ANAs) are found in both SLE and SSc . Increasing evidence from recent studies indicates that lncRNAs help regulate the immune system and might specifically play a critical role in human autoimmune diseases …”

Section: Introduction Of Lncrnasmentioning

confidence: 99%

“…SLE, which has a high incidence rate in young women, is a complex systemic AID that involves both the innate and acquired immune systems . SLE loses its immune tolerance to nuclear autoantigens and produces ANAs.…”

Section: Introduction Of Lncrnasmentioning

confidence: 99%

See 3 more Smart Citations

Long noncoding RNAs in autoimmune diseases

Lei

Jin

et al. 2018

J Biomedical Materials Res

View full text Add to dashboard Cite

With the completion of the human genome project and further development of high‐throughput genomic technologies, interest in long noncoding RNAs (lncRNAs), which are defined as non‐protein‐coding RNAs at least 200 nucleotides in length, has strongly increased, and lncRNAs have become a major research direction. Increasing evidence demonstrates that lncRNAs are closely related to human growth and development and to disease occurrence via various mechanisms. lncRNAs also play crucial roles in the differentiation and activation of immune cells, and their relationships with human autoimmune diseases have received increasing attention. The development of biotechnology has led to the gradual discovery of many potential lncRNA functions. In this review, we discuss various lncRNAs that have been implicated in different human autoimmune diseases, focusing on their clinical applications as potential biomarkers and therapeutic targets in the pathologies of diverse human autoimmune diseases. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 468–475, 2019.

show abstract

Section: Lncrnas and Human Autoimmune Diseasesmentioning

confidence: 99%

Section: Lncrnas and Human Autoimmune Diseasesmentioning

confidence: 99%

Section: Introduction Of Lncrnasmentioning

confidence: 99%

Section: Introduction Of Lncrnasmentioning

confidence: 99%

See 2 more Smart Citations

Long noncoding RNAs in autoimmune diseases

Lei

Jin

et al. 2018

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…Collectively, our data suggests that treatment of lupus with immunotherapeutics that selectively expand endogenous CD8 T and NK cells should be approached with caution and may not achieve the therapeutic effect of similar agents that has been observed in multiple sclerosis. Moreover, the increased risk of hematologic malignancy in patients with lupus 65 may complicate clinical application of N-803 or other antitumor therapeutics with the potential to aggravate autoimmune sequelae in these patients. On the other hand, NK cells are potent antitumor effector cells, and selective expansion of these cells without concurrent autoimmune-exacerbation by T cells may provide clinically valuable anti-leukemic effects even if these NK cells are unable to alleviate underlying elements of lupus-like disease.…”

Section: Discussionmentioning

confidence: 99%

Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease

Reighard

Krishnamurthy

Cevik

et al. 2019

Preprint

View full text Add to dashboard Cite

Certain therapies (i.e. daclizumab) that promote expansion of natural killer (NK) cells are associated with clinical amelioration of disease in the context of multiple sclerosis and associated mouse models. The clinical benefits are putatively attributable to an enhanced capacity of NK cells to kill activated pathogenic T cells. Whether a parallel approach will also be effective in systemic lupus erythematosus (lupus), a multi-organ autoimmune disease driven by aberrant responses of self-reactive T and B cells, is unclear. In the present study we assess the therapeutic impact of IL-2 and IL-15-based strategies for expanding NK cells on measures of lupus-like disease in a mouse model. Unexpectedly, cytokine-mediated expansion of cytotoxic lymphocytes aggravated immunological measures of lupus-like disease. Depletion studies reveal that the negative effects of these cytokine-based regimens are largely mediated by expansion of CD8 T cells rather than NK cells. These results provoke caution in the use of cytokine-based therapeutics to treat co-morbid cancers in patients with lupus and highlight the need for new methods to selectively expand NK cells in order to further assess their clinical value in autoimmune disease.Lupus | SLE | CD8 T | NK cell | IL-15 | IL-2 | Immunotherapy | TFH

show abstract

Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

Cobo‐Ibáñez

Urruticoechea‐Arana

Rúa-Figueroa

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To estimate the incidence and analyze any cancer-associated factors in patients with systemic lupus erythematosus (SLE), differentiating between hormone-sensitive (HS) and non-HS cancers.Methods. This was a retrospective multicenter study of a patient cohort from the Systemic Lupus Erythematosus Registry of the Spanish Society of Rheumatology. Included were the first cancer post-SLE diagnosis, clinical and sociodemographic information, cumulative damage, severity, comorbidities, treatments, and refractoriness. Cancers were classified as HS (prostate, breast, endometrium, and ovarian) and non-HS (the remainder). The standardized incidence ratio (SIR) was calculated and logistic regression models were built.Results. A total of 3,539 patients (90.4% women) were included, 154 of whom had cancer (91% female), and 44 had HS cancer (100% female). The cancer SIR was 1.37 (95% confidence interval [95% CI] 1.15-1.59), with higher values in women age <65 years (SIR 2.38 [95% CI 1.84-2.91]). The SIR in women with HS versus non-HS cancer was 1.02 (95% CI 0.13-1.91) and 1.93 (95% CI 0.98-2.89). In HS versus non-HS cancers, SLE diagnostic age (odds ratio [OR] 1.04 [P = 0.002] versus 1.04 [P = 0.019]), and period of disease evolution (OR 1.01 [P < 0.001] versus 1.00 [P = 0.029]) were associated with cancer. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (OR 1.27 [P = 0.022]) and angiotensin-converting enzyme (ACE) inhibitor prescriptions (OR 2.87 [P = 0.048]) were associated with non-HS cancers.Conclusion. Cancer incidence in patients with SLE was higher than in the Spanish population, particularly among young women. This increase might be due to non-HS cancers, which would be associated with SLE involving greater cumulative damage where more ACE inhibitors are prescribed. * Values are the number (%) unless indicated otherwise. SLE = systemic lupus erythematosus; SLEDAI = Systemic Lupus Erythematosus Disease Activity Index; IQR = interquartile range; SDI = Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index; ACE = angiotensin-converting enzyme. † The score corresponding to cancer was excluded when calculating the index.

show abstract

A review on SLE and malignancy

Cited by 65 publications

References 144 publications

Long noncoding RNAs in autoimmune diseases

Long noncoding RNAs in autoimmune diseases

Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease

Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About